It with some relief that we find this odd named stock is not high tech but directed at the world of research in medical... Like AVTR a bit Company Profile IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina.
Originally-> Quintiles IMS Holdings, Inc. Now--> IQVIA Holdings ? would of loved being in that board meeting when the name change was proposed. Quintiles is cool
It's an interesting find. At first glance I see they are carrying a ton of debt. We'll have to see what that's about. But I thought you didn't want expensive (by price) stocks. $189K for 1000 shares. I'm not gonna dig into it if you're gonna move on and forget about it by tomorrow.
I was gonna tell you that. Or maybe I did. There was a 100K share block trade yesterday at $9.25 None today yet. I should have the new short #'s here today for May 15th. It jumped from 1.06M shares short to 1.14M from 4/15 to 4/28 ... not too bad really. Yesterday and today already, whoever opened those June $7.50 puts is working on closing them. That's a good sign. But the open interest has jumped to 7K. I think we're gonna hear something pretty soon Stoney. Maybe within 2 weeks.
I hear you on stock price there and you are correct. I would never buy 1,000. But in tech specifically, finding it hard to find truly undervalued names-- so I have RELL which i really like but I thought maybe split the purchase up if it was 1,000 RELL at --$17,000 I would go with RELL and some name that has fallen from the sky. My son suggested TEAM which I thought was a cool idea. Atlassian. There are some names that are way down but still expensive. Barbell.
Stoney I dunno. TEAM is a fast grower, or it has been, I haven't followed it in awhile, but they still aren't profitable and it's still priced to perfection even down here at $141. That's the reason I like PSTG. They have $1B in cash.. AND.... they turn a profit. Forward PE is forecast at 17. PSTG has earnings coming up, and the fact that it's still not above $25 certainly gives me pause... so it could go lower... but between the two, if I had to pick, it would be PSTG.